Enzalutamide Improves Overall Survival for Advanced Castration-Resistant Prostate Cancer

Phase III results support use of enzalutamide in prostate cancer patients with early metastatic disease. 

ESMO members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.